Chronic Hepatitis C and Normal ALT: Considerations for Treatment

Bacon, Bruce R.
September 2004
American Journal of Gastroenterology;Sep2004, Vol. 99 Issue 9, p1706
Academic Journal
Improvements in the treatment of patients with chronic hepatitis C have progressed over the past 14 yr. Initially, treatment of patients with persistently normal ALT levels was not considered necessary. As treatment response improved, more of these patients were treated. Jacobson and colleagues have shown that patients with normal ALT levels respond similarly to those with elevated ALT levels when treated with the combination of interferon and ribavirin. ALT levels are a poor marker of disease severity and/or indication for treatment in patients with chronic hepatitis C.(Am J Gastroenterol 2004;99:1706-1707)


Related Articles

  • A Novel Ex Vivo Assay of Interferon-Based Suppression, to Predict the Outcome of Antiviral Therapy for Hepatitis C. Chau-Ting Yeh; Chao-Wei Hsu; Ming-Ling Chang; I-Shyan Sheen; Shi-Ming Lin; Chun-Jung Lin; Chen-Chun Lin; Yi-Cheng Chen; Jeng-Chang Chen // Journal of Infectious Diseases;5/15/2006, Vol. 193 Issue 10, p1365 

    An ex vivo liver slice-culture method was used to develop a novel assay of pretherapy interferon-based suppression. To evaluate its clinical application, 45 consecutive patients with chronic hepatitis C were included. They underwent the ex vivo antiviral assay, followed by a 24-week course of...

  • New drugs: simeprevir, sofosbuvir, and dolutegravir sodium. Hussar, Daniel A.; Zhimeng Jenny Jin // Journal of the American Pharmacists Association: JAPhA;Mar/Apr2014, Vol. 54 Issue 2, p202 

    The article presents information on three hepatitis C virus infection drugs including simeprevir, sofosbuvir and dolutegravir.

  • Hepatitis C Virus (HCV)-Specific T Cell Responses in Injection Drug Users with Apparent Resistance to HCV Infection. Thurairajah, Prem H.; Hegazy, Doha; Chokshi, Shilpa; Shaw, Steve; Demaine, Andrew; Kaminski, Edward R.; Naoumov, Nikolai V.; Cramp, Matthew E. // Journal of Infectious Diseases;12/15/2008, Vol. 198 Issue 12, p1749 

    Background. Injection drug users (IDUs) are at risk of acquiring hepatitis C virus (HCV) infection. We have identified a cohort of long-term IDUs who remain uninfected by HCV despite high-risk behavior. We have categorized these subjects as "exposed uninfected" and have sought immunological...

  • Short-Term Treatment and Sustained Virologic Response in Two Chronic Hepatitis C Cases. Erol, Serpil; Parlak, Mehmet // Medical Journal of Trakya University / Trakya Universitesi Tip F;2010, Vol. 27 Issue 1, p92 

    The standard treatment for chronic hepatitis C infection is the combination of pegylated interferon-alpha (Peg-IFN-α) and ribavirin for 48 weeks in patients infected with genotype-1. In genotype-2 or -3 infections, treatment by either conventional IFN-α and ribavirin or Peg-IFN-α with...

  • STAT-C + standard therapy cost effective in hep C.  // PharmacoEconomics & Outcomes News;12/1/2007, Issue 542, p4 

    The article focuses on the findings of a study on the cost effectiveness of adding a Specifically Targeted Antiviral Therapy for hepatitis C virus (STAT-C) to standard therapy in patients with genotype 1 chronic hepatitis C infection. It cites that the regimens including STAT-C would be...

  • Ribavirin Monotherapy for Chronic Hepatitis C Infection: A Cochrane Hepato-Biliary Group Systematic Review and Meta-Analysis of Randomized Trials. Brok, Jesper; Gluud, Lise L.; Gluud, Christian // American Journal of Gastroenterology;Apr2006, Vol. 101 Issue 4, p842 

    OBJECTIVES: Adding ribavirin to interferon improves treatment response for patients with chronic hepatitis C, but the effects of ribavirin monotherapy are unclear. We conducted a systematic review to assess the benefits and harms of ribavirin monotherapy for patients with chronic hepatitis C....

  • Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature. Slavenburg, Serena; Heijdra, Yvonne F.; Drenth, Joost P. H. // Digestive Diseases & Sciences;Mar2010, Vol. 55 Issue 3, p579 

    Combination of peginterferon and ribavirin is the current therapy for chronic hepatitis C infection (HCV). Interstitial pneumonitis is a rare side-effect of HCV therapy and is an important cause of dose reduction or discontinuation, impairing success of antiviral therapy. We performed a review...

  • Hepatitis C: staying the course. Garber, Ken // Nature Biotechnology;Dec2007, Vol. 25 Issue 12, p1379 

    The article reports on the studies conducted by biotechnological companies regarding the treatment of hepatitis C virus (HCV) in the U.S. HCV has infected an estimated 170 people worlwide. It states that the companies have abandoned or suspended at least eight antiviral drugs in clinical...

  • Nonresponder Patients with Hepatitis C Virus Genotype 2/3 Infection: A Question of Low Systemic Interferon Concentrations? Alsiö, Åsa; Christensen, Peer Brehm; Färkkilä, Martti; Langeland, Nina; Buhl, Mads Rauning; Pedersen, Court; Mørch, Kristine; Haagmans, Bart L.; Westin, Johan; Hellstrand, Kristoffer; Norkrans, Gunnar; Lagging, Martin // Clinical Infectious Diseases;2/15/2010, Vol. 50 Issue 4, pe22 

    Twelve of 303 per-protocol patients were nonresponders in a 12-week versus 24-week treatment study of hepatitis C virus (HCV) genotype 2/3 infection. The nonresponders had significantly lower interferon concentrations, as well as significantly greater mean age, body mass index, and viral load....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics